BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States.
The last earnings update was 37 days ago.
Discounted Cash Flow Calculation for DB:BX2 using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future cash flows to their present value using the 2 stage method.
We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
DB:BX2 DCF 1st Stage: Next 10 year cash flow forecast
Amount off the current price
is available for.
Share price is
vs Future cash flow value of
Current Discount Checks
to be considered undervalued it must be available for at least 20% below the
current price. Less than 40% is even better.
BioXcel Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
BioXcel Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
BioXcel Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
BioXcel Therapeutics's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if BioXcel Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
BioXcel Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
BioXcel Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
BioXcel Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
BioXcel Therapeutics has no long term commitments.
This treemap shows a more detailed breakdown of
BioXcel Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
BioXcel Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Vimal D. Mehta, Ph.D., is Co-founder of BioXcel Corporation and serves as its Chairman and Chief Executive Officer. He has been Chief Executive Officer, President and Secretary of BioXcel Therapeutics, Inc. since May 2017 and has been its Director since April 2017. Dr. Mehta served as Senior Vice President of Global Business Development at Galapagos Biotech Ltd. Dr. Mehta joined Galapagos Biotech Ltd. in 2002. He was formerly a senior business development manager at CuraGen Corporation, which he joined in 1996. Dr. Mehta has had a significant scientific and business career spanning over 15 years, with a successful background in establishing partnerships with pharmaceutical and biotechnology leaders in the USA, Europe and Japan. Dr. Mehta is a business development professional with an illustrious scientific and business career spanning 20 years. From 1990 to 1996, Dr. Mehta was resident at the University of Texas Southwestern Medical Center at Dallas, initially as a postdoctoral fellow and later as an assistant professor. Dr. Mehta holds a Ph.D. in Chemistry from the University of Delhi, India and completed a Post-Doctoral Fellowship in Chemistry at the University of Montpellier, France.
Vimal's compensation has increased whilst company is loss making.
Vimal's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the BioXcel Therapeutics management team is less than 2 years, this suggests a new team.
Chief Scientific Officer
Senior VP & Chief Medical Officer
Chief Financial Officer
VP of Finance & Chief Accounting Officer
VP and Head of Global Clinical Operations & Project Management
Head of Global Pharmaceutical Development and Operations & VP
Senior VP and Head of Translational Medicine
Vice President of Clinical Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the BioXcel Therapeutics board of directors is less than 3 years, this suggests a new board.
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA, Nektar Therapeutics, and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.